Assessing unintended hybridization-induced biological effects of oligonucleotides
Morten Lindow, Arthur A. Levin(Miragen Therapeutics (United States)), Laurence O. Whiteley(Pfizer (United States)), James D. Thompson(Quark Pharmaceuticals (United States)), Hans‐Peter Vornlocher, Joanne Kamens(Massachusetts Academy of Math and Science at WPI), Julja Burchard(United States Military Academy), Steven R. Bartz(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scott P. Henry(Ionis Pharmaceuticals (United States)), Douglas J. Kornbrust(HealthInsight), Husam S. Younis(Ionis Pharmaceuticals (United States)), Saraswathy V. Nochur(Université Paris-Sud), Donald E. Riley(Central Washington University), Joel D. Parry(Age UK)
Cited by 108
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
|New England Journal of Medicine|2013|961
Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation
|PLoS ONE|2010|127
<i>In silico</i>and<i>in vitro</i>evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization
|Nucleic Acids Research|2015|109
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|Advanced Drug Delivery Reviews|2014|91